Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Prepaid Assets (2021 - 2025)

ARS Pharmaceuticals' Prepaid Assets history spans 5 years, with the latest figure at $1.3 million for Q3 2025.

  • For Q3 2025, Prepaid Assets rose 10.94% year-over-year to $1.3 million; the TTM value through Sep 2025 reached $1.3 million, up 10.94%, while the annual FY2024 figure was $6.9 million, 512.63% up from the prior year.
  • Prepaid Assets for Q3 2025 was $1.3 million at ARS Pharmaceuticals, down from $6.9 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $7.5 million in Q1 2022 and bottomed at $400000.0 in Q2 2024.
  • The 5-year median for Prepaid Assets is $3.3 million (2021), against an average of $3.6 million.
  • The largest annual shift saw Prepaid Assets tumbled 83.58% in 2023 before it soared 512.63% in 2024.
  • A 5-year view of Prepaid Assets shows it stood at $7.4 million in 2021, then tumbled by 55.43% to $3.3 million in 2022, then tumbled by 66.13% to $1.1 million in 2023, then skyrocketed by 512.63% to $6.9 million in 2024, then tumbled by 81.44% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Prepaid Assets are $1.3 million (Q3 2025), $6.9 million (Q4 2024), and $1.2 million (Q3 2024).